The NY Times: Remdesivir Fails to Prevent Covid-19 Deaths in Huge Trial

59

A new study by the World Health Organization showed that the antiviral drug Remdesivir, which was previously granted emergency authorization by the Food and Drug Administration, fails to prevent death among COVID-19 patients. The study’s manuscripts suggest that the results of Remdesivir were “unpromising” and are sufficient to “refute early hopes.” A previous trial by the National Institutes of Health showed that Remdesivir modestly reduced the time to recovery in hospitalized patients. The drug was also administered to President Trump after he began to observe symptoms earlier this month. For more information on this study, click here.

Comments are closed.

Skip to toolbar